1. (EMA), E.M.A (2009a) EPAR summary for the public: Eporatio - epoetin theta. Available from:
https://www.ema.europa.eu/en/documents/overview/eporatio-epar-summary-public_en.pdf
2. (EMA), E.M.A (2009b) EPAR summary for the public: Biopoin - epoetin theta. Available from:
https://www.ema.europa.eu/en/documents/overview/biopoin-epar-summary-public_en.pdf
3. (EMA), E.M.A (2012) EPAR summary for the public: Mircera - methoxy polyethylene glycol-epoetin beta. Available from:
https://www.ema.europa.eu/en/documents/overview/mircera-epar-summary-public_en.pdf
4. (EMA), E.M.A (2015a) Public summary of opinion on orphan designation: filgrastim for the treatment of amyotrophic lateral sclerosis. Available from:
https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/532-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-amyotrophic-lateral_en.pdf
5. (EMA), E.M.A (2015b) Public summary of opinion on orphan designation: filgrastim for the treatment of spinal cord injury. Available from:
https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/580-public-summary-positive-opinion-orphan-designation-filgrastim-treatment-spinal-cord-injury_en.pdf